<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914808</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9667</org_study_id>
    <nct_id>NCT02914808</nct_id>
  </id_info>
  <brief_title>Oedema Study : Chroedem</brief_title>
  <acronym>CHROEDEM</acronym>
  <official_title>Assessment of Tissue and Biomolecular Complements of Lower Limb Chronic Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chroedem study is aiming to assess tissue and biomolecular components of chronic lower&#xD;
      limb oedema (CO). The investigators working hypothesis is that according to the aetiology of&#xD;
      CO, the proportion of oedema &amp; composition of peri-oedema tissues (fat, muscle,&#xD;
      fibrosis/inflammation) might differ and could at least in part explain differences in&#xD;
      failure/success of compressive therapies from one patient to another. For that purpose, 24&#xD;
      patients with a post-thrombotic syndrome (PTS)-related oedema and 24 patients with a primary&#xD;
      lymphedema will undergo a magnetic resonance imaging (MRI)) of the legs and biological&#xD;
      (genetic) testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lower limb oedema is the consequence of an abnormal accumulation of fluid in the&#xD;
      interstitium located beneath the skin of legs. It is a frequent disease with a significant&#xD;
      morbidity (skin infections, leg ulcers…), which can deeply alter patient's quality of life.&#xD;
&#xD;
      On a pathological point of view, current main hypothesis is hemodynamic (i.e. failure of&#xD;
      venous and lymphatic return).&#xD;
&#xD;
      Recent data suggest that other factors, particularly genetic ones (genes coding for proteins&#xD;
      of inflammation or of fibrosis, for adipogenesis and for lymphangiogenesis…) could influence&#xD;
      the development of CO. Stimulation of these mediators varies from one person to another and&#xD;
      from one clinical setting to another (i.e. venous insufficiency vs. lymphedema etc…). One can&#xD;
      therefore assume that CO is not a homogeneous entity and that the distribution of tissue&#xD;
      components varies.&#xD;
&#xD;
      On a therapeutic point of view, this difference in the distribution of tissue components&#xD;
      could at least in part explain the differences in effectiveness of compression therapy and in&#xD;
      tissue dysmorphia from one person to another and from one type of CO to another.&#xD;
&#xD;
      The study primary objective is to assess and compare by MRI the different tissue components&#xD;
      (oedema, fat, muscle, inflammation/fibrosis) of lower limb CO of venous vs. lymphatic&#xD;
      origins.&#xD;
&#xD;
      The investigators shall conduct a prospective observational pilot study. 24 patients with a&#xD;
      CO of PTS origin and 24 patients with a CO of lymphatic origin (primary lymphoedema) will&#xD;
      undergo a clinical examination, 3-D laser scanner volumetry of their lower limbs, blood tests&#xD;
      and a MRI of lower limb. Main exclusion criteria will be obesity and bilateral CO. The main&#xD;
      primary outcome measure will be the proportion of fat, muscle and oedema assessed by MRI in a&#xD;
      pre-determined lower limb area. The main secondary outcome measure will be the prevalence in&#xD;
      each group of i) variations in exonic sequence of genes coding for proteins of&#xD;
      inflammation/fibrosis, angiogenesis, adipogenesis; ii) variations in exonic sequence of genes&#xD;
      reported in the literature as associated with primary lymphoedema.&#xD;
&#xD;
      This study should allow to better characterize tissue structure and inflammatory, adipous and&#xD;
      angio-genetic profiles of lower limb CO. The potential therapeutic perspective is to adapt&#xD;
      compressive therapies to the type of oedema and to test the impact of new therapies (e.g.&#xD;
      anti-inflammatory drugs for oedema with important fibrotic component?).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of fat muscle and oedema assessed by MRI in a pre determined lower limb area</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lower Limb Chronic Oedema</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients will undergo a lower limb MRI and blood tests</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        24 patients with a CO of PTS origin and 24 patients with a CO of lymphatic origin (primary&#xD;
        lymphoedema) will undergo a clinical examination, 3-D laser scanner volumetry of their&#xD;
        lower limbs, blood tests and a MRI of lower limb. Main exclusion criteria will be obesity&#xD;
        and bilateral CO.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Lower limb CO secondary to PTS or Primary lymphoedema (We will include secondary&#xD;
             lymphedema of the lower limbs only if the matcing constraints on age and length of&#xD;
             evolution do not allow pairing)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Bilateral CO&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
          -  Mixed CO (PTS and lymphatic origins)&#xD;
&#xD;
          -  CO of other origin : Heart failure, hepatic or renal impairment&#xD;
&#xD;
          -  Denutrition&#xD;
&#xD;
          -  Contra-indication to MRI&#xD;
&#xD;
          -  Patient not affiliated to French Health Insurance System&#xD;
&#xD;
          -  Patient protected by the law&#xD;
&#xD;
          -  Patient refusing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ISABELLE QUERE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ISABELLE QUERE, MD, PhD</last_name>
    <phone>(0)4 67 33 70 25</phone>
    <phone_ext>+33</phone_ext>
    <email>i-quere@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pr Sophie BLAISE</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie BLAISE, PhD</last_name>
      <phone>(0)476765547</phone>
      <phone_ext>+33</phone_ext>
      <email>sblaise@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISABELLE QUERE, MD, PhD</last_name>
      <phone>(0)4 67 33 70 25</phone>
      <phone_ext>+33</phone_ext>
      <email>jp-galanaud@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JEAN CHRISTOPHE JCG GRIS, MD PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

